Sodium valproate in aggressive bahaviour in dementia: A twelve-week open label follow-up study

International Journal of Geriatric Psychiatry

Volumn 19, Issue 4, 2004, Pages 305-312

  Sival, Rob C ^a   Duivenvoorden, Hugo J ^b   Jansen, Paul A F ^c   Haffmans, P M Judith ^a   Duursma, Sijmen A ^c   Eikelenboom, Piet ^d  

^a PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d GGZ Buitenamstel ^*  (Netherlands)

Author keywords

Aggressive behaviour; Dementia; Disturbed behaviour; Sodium valproate

Indexed keywords

PLACEBO; VALPROIC ACID;

AGED; AGGRESSION; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DISORIENTATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; GERONTOPSYCHIATRY; HUMAN; MALE; MEDICAL DECISION MAKING; MORTALITY; NURSING HOME; PRESCRIPTION; PSYCHIATRIC DEPARTMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOCIAL BEHAVIOR; TEACHING HOSPITAL;

AGED; AGED, 80 AND OVER; AGGRESSION; ANALYSIS OF VARIANCE; ANTIMANIC AGENTS; DEMENTIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SOCIAL BEHAVIOR DISORDERS; VALPROIC ACID;

EID: 1842688806     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1034     Document Type: Article

References (38)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV), 4th edn. APA: Washington, DC.
2. Burns A, Lewis G, Jacoby R, Levy R. 1991. Factors affecting survival in Alzheimer's disease. Psychological Med 21: 363-370.
3. Calabrese JR, Delucchi GA. 1990. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147: 431-434.
4. Camargo O, Preston G. 1945. What happen to the patients who are hospitalised for the first time when over 65 years of age. Am J Psychiatry 102: 168-173.
5. Chambers CA, Bain J, Rosbuttum R, Ballinger BR, McLarens S. 1982. Carbamazepine in senile dementia and overactivity - a placebo controlled double blind trial. Med Sci 10: 505-506.
6. De Deyn PP, Rabheru K, Rasmussen A, et al. 1999. A randomised trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology 53: 946-955.
7. Devanand DP, Jacobs DM, Tang M, et al. 1997. The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry 54: 257-263.
8. Devenand DP, Marder K, Michaels KS, et al. 1998. A randomised, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviours in Alzheimer's disease. Am J Psychiatry 155: 1512-1520.
9. Eustace A, Coen R, Walsh C, et al. 2002. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 17: 968-973.
10. Folstein ME, Folstein SE, McHugh PR. 1975. 'Mini-mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12: 189-198.
11. Goldfarb A. 1969. Predicting mortality in the institutionalised aged. Arch Gen Psychiatry 21: 172-176.
12. Guy W. 1976. ECDEU, Assessment Manual for Psychopharmacology. US Department of Health, Education and Wellfare: Rockville.
13. Haupt M, Kurz A, Jänner M. 2000. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 11: 147-152.
14. Hayes SG. 1989. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 50(S3): 35-39.
15. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R. 1999. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. Br J Psychiatry 174: 39-44.
16. Hughes CP, Berg L, Danzinger WL, Cohen LA, Martin RL. 1982. A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566-572.
17. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. 1999. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomised, double blind trial. J Clin Psychiatry 60: 107-115.
18. Kay D. 1962. Outcome and cause of death in mental disorders of old age: A longer term follow-up of functional and organic psychosis. Acta Psychiatrica Scandinavica 38: 249-276.
19. Laird NM, Ware JH. 1982. Random-effects models for longitudinal data. Biometrics 38: 963-974.
20. Little RJA, Rubin DB. 1987. Statistical Analysis with Missing Data. John Wiley: New York.
21. Mazure CM, Druss BG, Cellar JS. 1992. Valproate treatment of older patients with organic mental syndromes and behavioural dyscontrol. J Am Geriatr Soc 40: 914-916.
22. McFarland B, Miller MR, Straumfjord AA. 1990. Valproate use in the older manic patient. J Clin Psychiatry 51: 479-481.
23. McKhann G, Brackman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA workgroup under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
24. Porsteinsson AP, Tariot PN, Erb R, et al. 2001. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9: 58-66.
25. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. 2003. Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial. Am J Geriatr Psychiatry 11: 434-440.
26. Schneider LS, Pollock VE, Lyness SA. 1990. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38: 553-563.
27. Shah K, Banks G, Merskey H. 1969. Survival in arteriosclerotic and senile dementia. Br J Psychiatry 115: 1283-1286.
28. Shen DD. 1999. Absorption, distribution, and excretion. In Milestones in Drug Therapy: Valproate, Löscher W (ed.). Birkhä user: Basel; 77-90.
29. Sival RC, Albronda T, Haffmans PMJ, Saltet ML, Schellekens CMAM. 2000. Is aggressive behaviour influenced by the use of a behaviour rating scale in patients in a psychogeriatric nursing home? Int J Geriatr Psychiatry 15: 108-111.
30. Sival RC, Haffmans PMJ, Jansen PAF, Duursma SA, Eikelenboom P. 2002. Sodium valproate in the treatment of aggressive behaviour in patients with dementia - a randomised placebo-controlled clinical trial. Int J Geriatr Psychiatry 17: 579-585.
31. Street JS, Clark WC, Gannon KS, et al. 2000. Olanzapine treatment of psychotic and al symptoms in patients with Alzheimer disease in nursing care facilities. A double blind randomised placebo-controlled trial. Arch Gen Psychiatry 57: 968-976.
32. Tariot PN, Erb R, Podgorski CA, et al. 1998. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155: 54-61.
33. Tariot PN. 1999. Treatment of agitation in dementia. J Clin Psychiatry 60(Suppl. 8): 11-20.
34. Tariot PN, Schneider LS, Mintzer JE, et al. 2001. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr Therapeut Res 62: 51-67.
35. Verbeke G, Molenberg G. 2000. Linear Models for Longitudinal Data. Springer: Berlin.
36. Verstraten PFJ, van Eekelen CWJM. 1987. Handleiding van de GIP: Gedragsobservatie-schaal voor de intramurale Psychogeriatrie. Van Loghum Slaterus: Deventer.
37. Verstraten PFJ. 1988. The GIP: An observational ward behaviour scale. Psychopharmacol Bull 24: 717-719.
38. Wistedt B, Rasmussen A, Pedersen L, et al. 1990. The development of an observer-scale for measuring social dysfunction and aggression. Pharmaco Psychiatry 23: 249-252.